These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9056587)

  • 41. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update on the statistical analysis of bioequivalence studies.
    Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S45-50. PubMed ID: 1601531
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comment on so-called individual criteria of bioequivalence.
    Wellek S
    J Biopharm Stat; 1997 Mar; 7(1):17-21. PubMed ID: 9056583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generic drug substitution.
    Rogowski A; Lemay V
    Med Health R I; 2001 Jul; 84(7):241-4. PubMed ID: 11482281
    [No Abstract]   [Full Text] [Related]  

  • 46. Sample size considerations for establishing clinical bioequivalence of allergen formulations.
    Rabin RL; Slater JE; Lachenbruch P; Pastor RW
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):24-33. PubMed ID: 15119019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessing individual bioequivalence with high-order cross-over designs: a unified procedure.
    Hsuan FC; Reeve R
    Stat Med; 2003 Sep; 22(18):2847-60. PubMed ID: 12953284
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update to the PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):571-2. PubMed ID: 10868306
    [No Abstract]   [Full Text] [Related]  

  • 49. Individual bioequivalence: attractive in principle, difficult in practice.
    Endrenyi L; Amidon GL; Midha KK; Skelly JP
    Pharm Res; 1998 Sep; 15(9):1321-5. PubMed ID: 9755880
    [No Abstract]   [Full Text] [Related]  

  • 50. Bioequivalent or nonbioequivalent?
    Rescigno A; Powers J; Herderick EE
    Pharmacol Res; 2001 Jun; 43(6):543-7. PubMed ID: 11419963
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium.
    ; ;
    Thyroid; 2004 Jul; 14(7):486. PubMed ID: 15307934
    [No Abstract]   [Full Text] [Related]  

  • 52. Controversies in bioequivalence studies.
    Steinijans VW; Hauschke D; Jonkman JH
    Clin Pharmacokinet; 1992 Apr; 22(4):247-53. PubMed ID: 1606785
    [No Abstract]   [Full Text] [Related]  

  • 53. A simple BASIC program for the calculation of nonparametric confidence intervals in bioequivalence testing.
    Meineke I
    Comput Methods Programs Biomed; 1987 Feb; 24(1):65-71. PubMed ID: 3829651
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tricyclics, bioequivalence, and clinical response.
    Ostroff RB; Docherty JP
    Am J Psychiatry; 1978 Dec; 135(12):1560-1. PubMed ID: 717581
    [No Abstract]   [Full Text] [Related]  

  • 55. Power of the two one-sided tests procedure in bioequivalence.
    Phillips KF
    J Pharmacokinet Biopharm; 1990 Apr; 18(2):137-44. PubMed ID: 2348380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioequivalence.
    Rescigno A
    Pharm Res; 1992 Jul; 9(7):925-8. PubMed ID: 1438007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An alternative derivation of the distribution of the individual bioequivalence metric.
    Bolton S; Sondhi M; DiLiberti C
    Drug Dev Ind Pharm; 2003 Apr; 29(4):469-74. PubMed ID: 12737539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comment: Thioridazine bioequivalence.
    Meyer HM
    Drug Intell Clin Pharm; 1986 Apr; 20(4):311-2. PubMed ID: 3698831
    [No Abstract]   [Full Text] [Related]  

  • 59. Approximate sample sizes for testing hypotheses about the ratio and difference of two means.
    Kieser M; Hauschke D
    J Biopharm Stat; 1999 Nov; 9(4):641-50. PubMed ID: 10576408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Mathematics in psychiatry (discussion)].
    Beschasnyĭ AA; Nemtsov AV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(2):144-6. PubMed ID: 2160159
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.